×
Enanta Pharmaceuticals Common Stock Net 2011-2024 | ENTA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Enanta Pharmaceuticals common stock net from 2011 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Enanta Pharmaceuticals Common Stock Net 2011-2024 | ENTA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Enanta Pharmaceuticals common stock net from 2011 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.8B
Chugai Pharmaceutical (CHGCY)
$66.9B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$20B
Astellas Pharma (ALPMY)
$17.7B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$16B
Neurocrine Biosciences (NBIX)
$15.3B
Shionogi (SGIOY)
$12.5B
Orion OYJ (ORINY)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Stevanato Group S.p.A (STVN)
$6.5B
Corcept Therapeutics (CORT)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.9B
Grifols, S.A (GRFS)
$4.8B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Recursion Pharmaceuticals (RXRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.1B
Hypermarcas (HYPMY)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Indivior (INDV)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Evotec AG (EVO)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.4B